Using CT scans to personalize treatment for pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have been diagnosed with IPF (a type of lung scarring) by your doctor
- You are willing and able to sign a consent form
- If you could become pregnant, you must agree to use two effective birth control methods (or abstain from sex) during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the genetics of idiopathic pulmonary fibrosis (IPF) and screens close family members for early signs. It aims to understand how IPF runs in families and may help find it earlier in relatives.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study compares two types of CT scans to see which one is better at identifying idiopathic pulmonary fibrosis (IPF), a specific type of interstitial lung disease. You may be able to join if you have been diagnosed with ILD and are being discussed by a team of specialists.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.